This article is free to access.
Background: In treatment-refractory liver dominant metastatic colorectal cancer, the role of liver directed therapies still is unclear. We sought to determine a prognostic score for Y90 radioembolization in these patients. Methods: We analyzed 106 patients with refractory liver dominant mCRC who had undergone a total of 178 Y90 radioembolizations with resin microspheres was collected. Potential factors influencing survival were analyzed using a Cox regression. The Log rank test served to establish prognostic factors and to form a clinical score for outcome prediction after Y90 radioembolization. Results: Median survival of all patients was 6.7months. Neither age nor prior surgical or systemic therapy nor metastatic spread had an effect on survival. In contrast, hepatic tumor load, Karnofsky index as well as CEA and CA19-9 serums level had a significant influence (p<0.001, p=0.037, p=0.023 and p<0.001, respectively). These three factors formed a score with 1 point each for tumor load >20%, CEA >130ng/ml or CA19-9>200U/ml and Karnofsky index <80%. Patients with a score of 0 and 1 displayed a median OS of 10.4months. Patients with a score of 2 and 3 demonstrated a median OS of 5.1months only (p<0.001). Conclusion: Overaggressive patient selection for Y90 radioembolization of liver dominant chemorefractory mCRC is of questionable benefit. A scoring system comprising hepatic tumor load, CEA and CA19-9 serum levels and Karnofsky index (TuCK-score) may support an improved patient selection. In our cohort of liver only versus liver dominant disease, extrahepatic lung or lymphatic metastases did not significantly alter the prognosis.
Damm, R., Seidensticker, R., Ulrich, G., Breier, L., Steffen, I. G., Seidensticker, M., … Ricke, J. (2016). Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: Outcome assessment applying a predictive scoring system. BMC Cancer, 16(1). https://doi.org/10.1186/s12885-016-2549-x